Portal de Periódicos da CAPES

Detection of Interleukin 2 in the Urine of Patients with Superficial Bladder Tumors after Treatment with Intravesical BCG

1986; Lippincott Williams & Wilkins; Volume: 136; Issue: 4 Linguagem: Inglês

10.1016/s0022-5347(17)45142-1

1527-3792

Eric O. Haaff, William J. Catàlona, Timothy L. Ratliff,

Infectious Disease Case Reports and Treatments

No AccessJournal of Urology1 Oct 1986Detection of Interleukin 2 in the Urine of Patients with Superficial Bladder Tumors after Treatment with Intravesical BCG Eric O. Haaff, William J. Catalona, and Timothy L. Ratliff Eric O. HaaffEric O. Haaff , William J. CatalonaWilliam J. Catalona , and Timothy L. RatliffTimothy L. Ratliff View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)45142-1AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Adjuvant intravesical BCG therapy is an effective means of treating superficial bladder tumors. The mechanism by which BCG mediates antitumor activity is not known; however, clinical and animal studies suggest that immunological responsiveness to BCG antigens correlates with antitumor activity. In this report the detection of interleukin 2 (IL-2, a lymphokine produced in response to BCG) in urine specimens of patients treated with intravesical BCG is reported. Patients with superficial transitional cell carcinoma of the bladder received intravesical BCG once each week for six weeks. No intradermal injections were administered. Urine specimens were obtained prior to BCG instillation and four, eight and 24 hours afterwards. The specimens were dialysed, concentrated five-fold and assayed for the presence of IL-2 in a biological assay using an IL-2 dependent cultured T-cell line. IL-2 was detected in urine but not serum after intravesical BCG instillation. IL-2 was characterized by absorption against an IL-2-dependent T cell line and neutralization by monoclonal anti-IL-2 antibodies. No IL-2 was detected in specimens obtained prior to BCG instillation or from donors with no detectable bladder pathology. One of 10 urine specimens from patients with urinary tract infections had detectable IL-2 levels. IL-2 production generally peaked during the fourth to sixth intravesical BCG treatment. Production was short-term in that IL-2 levels peaked four to eight hours after BCG instillation and were rarely (six of 54 specimens) observed 24 hours after instillation. Mean IL-2 levels were higher in patients who were rendered tumor free after BCG therapy but statistical significance was not achieved. Ten of 12 patients (83%) who responded to BCG therapy had urine IL-2 levels ≥1.6 units/ml. at least once during the six week treatment period while two of six (33%) patients not responding to therapy had similar urine IL-2 levels. These results show that intravesical BCG therapy induces the production of lymphokines including IL-2. The presence of BCG-induced lymphokines may be associated with anti-tumor activity. © 1986 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byBisiaux A, Thiounn N, Timsit M, Eladaoui A, Chang H, Mapes J, Mogenet A, Bresson J, Prié D, Béchet S, Baron C, Sadorge C, Thomas S, Albert E, Albert P and Albert M (2018) Molecular Analyte Profiling of the Early Events and Tissue Conditioning Following Intravesical Bacillus Calmette-Guerin Therapy in Patients With Superficial Bladder CancerJournal of Urology, VOL. 181, NO. 4, (1571-1580), Online publication date: 1-Apr-2009.Griffith T (2018) Predicting Bacillus Calmette-Guerin Immunotherapy EffectivenessJournal of Urology, VOL. 178, NO. 6, (2247-2248), Online publication date: 1-Dec-2007.BÖHLE A and BRANDAU S (2018) Immune Mechanisms in Bacillus Calmette-Guerin Immunotherapy for Superficial Bladder CancerJournal of Urology, VOL. 170, NO. 3, (964-969), Online publication date: 1-Sep-2003.DE BOER E, ROOIJAKKERS S, SCHAMHART D and KURTH K (2018) Cytokine Gene Expression in a Mouse Model: The First Instillations With Viable bacillus Calmette-Guerin Determine the Succeeding Th1 ResponseJournal of Urology, VOL. 170, NO. 5, (2004-2008), Online publication date: 1-Nov-2003.SAINT F, PATARD J, MAILLE P, SOYEUX P, HOZNEK A, SALOMON L, ABBOU C and CHOPIN D (2018) PROGNOSTIC VALUE OF A T HELPER 1 URINARY CYTOKINE RESPONSE AFTER INTRAVESICAL BACILLUS CALMETTE-GUERIN TREATMENT FOR SUPERFICIAL BLADDER CANCERJournal of Urology, VOL. 167, NO. 1, (364-367), Online publication date: 1-Jan-2002.ELSÄSSER-BEILE U, GUTZEIT O, BAUER S, KATZENWADEL A, SCHULTZE-SEEMANN W and WETTERAUER U (2018) SYSTEMIC AND LOCAL IMMUNOMODULATORY EFFECTS OF INTRAVESICAL BCG THERAPY IN PATIENTS WITH SUPERFICIAL URINARY BLADDER CARCINOMASJournal of Urology, VOL. 163, NO. 1, (296-299), Online publication date: 1-Jan-2000.Davidoff R, Yamaguchi R, Leach G, Park E and Lad P (2018) Multiple Urinary Cytokine Levels of Bacterial CystitisJournal of Urology, VOL. 157, NO. 5, (1980-1985), Online publication date: 1-May-1997.Sander B, Damm O, Gustafsson B, Andersson U and Hakansson L (2018) Localization of IL-1, IL-2, IL-4, IL-8 and TNF in Superficial Bladder Tumors Treated with Intravesical Bacillus Calmette-GuerinJournal of Urology, VOL. 156, NO. 2, (536-541), Online publication date: 1-Aug-1996.de Reijke T, de Boer E, Kurth K and Schamhart D (2018) Urinary Cytokines During Intravesical Bacillus Calmetteguerin Therapy for Superficial Bladder Cancer: Processing, Stability and Prognostic ValueJournal of Urology, VOL. 155, NO. 2, (477-482), Online publication date: 1-Feb-1996.Ratliff T (2018) Commentary on Interleukin-6 and BCG TherapyJournal of Urology, VOL. 154, NO. 2, (346-346), Online publication date: 1-Aug-1995.Hayashi O, Akashi M, Fujime Μ, Hanazawa K and Kitagawa R (2018) Detection of Interleukin-1 Activity in Human Bladder Cancer Cell LinesJournal of Urology, VOL. 151, NO. 3, (750-753), Online publication date: 1-Mar-1994.Martins S, Darlin D, Lad P and Zimmern P (2018) Interleukin-1B: A Clinically Relevant Urinary MarkerJournal of Urology, VOL. 151, NO. 5, (1198-1201), Online publication date: 1-May-1994.Böhle A, Thanhäuser A, Ulmer A, Ernst M, Flad H and Jocham D (2018) Dissecting the Immunobiological Effects of Bacillus Calmette-Guérin (BCG) In Vitro: Evidence of a Distinct BCG-Activated Killer (BAK) Cell PhenomenonJournal of Urology, VOL. 150, NO. 6, (1932-1937), Online publication date: 1-Dec-1993.Cockett A, Davis R, Cos L and Wheeless L (2018) Bacillus Calmette-Guerin and Interleukin-2 for Treatment of Superficial Bladder CancerJournal of Urology, VOL. 146, NO. 3, (766-769), Online publication date: 1-Sep-1991.Steinberg G, Brendler C, Squire R and Isaacs J (2018) Experimental Intravesical Therapy for Superficial Transitional Cell Carcinoma in a Rat Bladder Tumor ModelJournal of Urology, VOL. 145, NO. 3, (647-653), Online publication date: 1-Mar-1991.Böhle A, Gerdes J, Ulmer A, Hofstetter A and Flad H (2018) Effects of Local Bacillus Calmette-Guerin Therapy in Patients with Bladder Carcinoma on Immunocompetent Cells of the Bladder WallJournal of Urology, VOL. 144, NO. 1, (53-58), Online publication date: 1-Jul-1990.Böhle A, Nowc C, Ulmer A, Musehold J, Gerdes J, Hofstetter A and Flad H (2018) Elevations of Cytokines Interleukin-1, Interleukin-2 and Tumor Necrosis Factor in the Urine of Patients after Intravesical Bacillus Calmette-Guerin ImmunotherapyJournal of Urology, VOL. 144, NO. 1, (59-64), Online publication date: 1-Jul-1990.Morales A (2018) This Month in Investigative Urology: The Production of Lymphokines Following BCG TherapyJournal of Urology, VOL. 144, NO. 5, (1246-1247), Online publication date: 1-Nov-1990.Carballido J, Alvarez-Mon M, Solovera J, Menéndez-Ondina L and Durántez A (2018) Clinical Significance of Natural Killer Activity in Patients with Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 143, NO. 1, (29-33), Online publication date: 1-Jan-1990.Bretton P, Herr H, Whitmore W, Badalament R, Kimmel M, Provet J, Oettgen H, Melamed M and Fair W (2018) Intravesical Bacillus Calmette-Guerin Therapy for in situ Transitional Cell Carcinoma Involving the Prostatic UrethraJournal of Urology, VOL. 141, NO. 4, (853-855), Online publication date: 1-Apr-1989.Tsujihashi H, Matsuda H, Uejima S, Akiyama T and Kurita T (2018) Immunoresponse of Tissue Infiltrating Lymphocytes in Bladder TumorsJournal of Urology, VOL. 141, NO. 6, (1467-1470), Online publication date: 1-Jun-1989.Hillyard R, Ladaga L and Schellhammer P (2018) Superficial Transitional Cell Carcinoma of the Bladder Associated with Mucosal Involvement of the Prostatic Urethra: Results of Treatment with Intravesical Bacillus Calmette-GuerinJournal of Urology, VOL. 139, NO. 2, (290-293), Online publication date: 1-Feb-1988.Nakamura K, Chiao J, Nagamatsu G and Addonizio J (2018) Monocyte Cytolytic Factor in Promoting Monocyte-Mediated Lysis of Bladder Cancer Cells by Bacillus Calmette-GuerinJournal of Urology, VOL. 138, NO. 4 Part 1, (867-870), Online publication date: 1-Oct-1987. Volume 136Issue 4October 1986Page: 970-974 Advertisement Copyright & Permissions© 1986 by The American Urological Association Education and Research, Inc.MetricsAuthor Information Eric O. Haaff More articles by this author William J. Catalona More articles by this author Timothy L. Ratliff More articles by this author Expand All Advertisement PDF downloadLoading ...